Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Prices $74M Public Offering

NEW YORK – Castle Biosciences said on Thursday that it has priced its underwritten public offering of 2 million shares of its common stock at $37 per share.

The Friendswood, Texas-based company expects gross proceeds of $74 million from the offering. In addition, Castle Bio has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of stock at the offering price. The offering is expected to close on June 29.

In a filing with the US Securities and Exchange Commission, the company said the principal purpose of the offering is to obtain additional capital to support its operations, and that it doesn't have any specific plan for the use of the net proceeds. However, Castle Bio noted that it does intend to use the proceeds to further support and increase its R&D activities — including those to support the development of its product pipeline — to expand its commercial organization, and for working capital and other general corporate purposes.

SVB Leerink and Baird are acting as joint book-running managers for the offering and representatives of the underwriters. Canaccord Genuity is a passive book-runner and BTIG is acting as co-manager for the offering.

The company's shares fell 2 percent to $38.52 in morning trading on the Nasdaq.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.